Effects of IP-751, Ajulemic Acid, on Bladder Overactivity Induced by Bladder Irritation in Rats

Urology

Volumn 70, Issue 1, 2007, Pages 202-208

  Hiragata, Shiro ^a,b   Ogawa, Teruyuki ^a,b   Hayashi, Yukio ^a   Tyagi, Pradeep ^a   Seki, Satoshi ^b   Nishizawa, Osamu ^b   de Miguel, Fernando ^a   Chancellor, Michael B ^a   Yoshimura, Naoki ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ACETIC ACID; AJULEMIC ACID; CYCLOPHOSPHAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CONTRACTION; BLADDER IRRITATION; BLADDER PRESSURE; CONTROLLED STUDY; CYSTOMETRY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; NONHUMAN; OVERACTIVE BLADDER; PRIORITY JOURNAL; RAT; URINARY FREQUENCY;

ANIMALS; FEMALE; INTERLEUKIN-1; RATS; RATS, SPRAGUE-DAWLEY; TETRAHYDROCANNABINOL; URINARY BLADDER, OVERACTIVE;

EID: 34447542356     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.02.069     Document Type: Article

References (21)

1. Adams I.B., and Martin B.R. Cannabis: pharmacology and toxicology in animals and humans. Addiction 91 (1996) 1585-1614
2. Ross S.A., El Sohly M.A., Sultana G.N., et al. Flavonoid glycosides and cannabinoids from the pollen of Cannabis sativa L. Phytochem Anal 16 (2005) 45-48
3. Carlini E.A. The good and the bad effects of (-) trans-delta-9-tetrahydrocannabinol (Delta 9-THC) on humans. Toxicon 44 (2004) 461-467
4. Rog D.J., Nurmikko T.J., Friede T., et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 65 (2005) 812-819
5. Strasser F., Luftner D., Possinger K., et al. Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled clinical trial from the Cannabis In Cachexia Study Group. J Clin Oncol 24 (2006) 3394-3400
6. Zurier R.B., Rossetti R.G., Lane J.H., et al. Dimethylheptyl-THC-11 oic acid: a nonpsychoactive antiinflammatory agent with a cannabinoid template structure. Arthritis Rheum 41 (1998) 163-170
7. Burstein S.H., Audette C.A., Breuer A., et al. Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic, and leukocyte antiadhesion activities. J Med Chem 35 (1992) 3135-3141
8. Burstein S.H., Friderichs E., Kogel B., et al. Analgesic effects of 1′,1′ dimethylheptyl-delta8-THC-11-oic acid (CT3) in mice. Life Sci 63 (1998) 161-168
9. Dajani E.Z., Larsen K.R., Taylor J., et al. 1′,1′-Dimethylheptyl-delta-8-tetrahydrocannabinol-11-oic acid: a novel, orally effective cannabinoid with analgesic and anti-inflammatory properties. J Pharmacol Exp Ther 291 (1999) 31-38
10. Dyson A., Peacock M., Chen A., et al. Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat. Pain 116 (2005) 129-137
11. Rhee M.H., Vogel Z., Barg J., et al. Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J Med Chem 40 (1997) 3228-3233
12. Burstein S.H., Karst M., Schneider U., et al. Ajulemic acid: a novel cannabinoid produces analgesia without a "high. " Life Sci 75 (2004) 1513-1522
13. Liu J., Li H., Burstein S.H., et al. Activation and binding of peroxisome proliferator-activated receptor gamma by synthetic cannabinoid ajulemic acid. Mol Pharmacol 63 (2003) 983-992
14. Malley S.E., and Vizzard M.A. Changes in urinary bladder cytokine mRNA and protein after cyclophosphamide-induced cystitis. Physiol Genomics 9 (2002) 5-13
15. Malan Jr. T.P., Ibrahim M.M., Deng H., et al. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 93 (2001) 239-245
16. Akerman S., Kaube H., and Goadsby P.J. Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. J Pharmacol Exp Ther 309 (2004) 56-63
17. Consroe P., Musty R., Rein J., et al. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 38 (1997) 44-48
18. Jaggar S.I., Hasnie F.S., Sellaturay S., et al. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 76 (1998) 189-199
19. Dmitrieva N., and Berkley K.J. Contrasting effects of WIN 55212-2 on motility of the rat bladder and uterus. J Neurosci 22 (2002) 7147-7153
20. Maggi C.A., Santicioli P., Giuliani S., et al. The capsaicin-sensitive innervation of the rat urinary bladder: further studies on mechanisms regulating micturition threshold. J Urol 136 (1986) 696-700
21. Karst M., Salim K., Burstein S., et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA 290 (2003) 1757-1762